Cargando…
PD‐L1 expression is mainly regulated by interferon gamma associated with JAK‐STAT pathway in gastric cancer
Despite multidisciplinary treatment for patients with advanced gastric cancer, their prognosis remains poor. Therefore, the development of novel therapeutic strategies is urgently needed, and immunotherapy utilizing anti‐programmed death 1/‐programmed death ligand‐1 mAb is an attractive approach. Ho...
Autores principales: | Mimura, Kousaku, Teh, Jun Liang, Okayama, Hirokazu, Shiraishi, Kensuke, Kua, Ley‐Fang, Koh, Vivien, Smoot, Duane T., Ashktorab, Hassan, Oike, Takahiro, Suzuki, Yoshiyuki, Fazreen, Zul, Asuncion, Bernadette R., Shabbir, Asim, Yong, Wei‐Peng, So, Jimmy, Soong, Richie, Kono, Koji |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5765310/ https://www.ncbi.nlm.nih.gov/pubmed/29034543 http://dx.doi.org/10.1111/cas.13424 |
Ejemplares similares
-
Combined inhibition of PD-1/PD-L1, Lag-3, and Tim-3 axes augments antitumor immunity in gastric cancer–T cell coculture models
por: Mimura, Kosaku, et al.
Publicado: (2021) -
Inhibition of mitogen-activated protein kinase pathway can induce upregulation of human leukocyte antigen class I without PD-L1-upregulation in contrast to interferon-γ treatment
por: Mimura, Kousaku, et al.
Publicado: (2014) -
Phospho-STAT1 expression as a potential biomarker for anti-PD-1/anti-PD-L1 immunotherapy for breast cancer
por: Nakayama, Yuko, et al.
Publicado: (2019) -
UGT1A6 Polymorphisms Modulated Lung Cancer Risk in a Chinese Population
por: Kua, Ley-Fang, et al.
Publicado: (2012) -
Determinants of variability of five programmed death ligand-1 immunohistochemistry assays in non-small cell lung cancer samples
por: Soo, Ross A., et al.
Publicado: (2018)